Cited by 2,898CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchImmunotherapy and Immune Responses

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Open access

Lee, Daniel W, Kochenderfer, James N, Stetler-Stevenson, Maryalice, Cui, Yongzhi K, Delbrook, Cindy, Feldman, Steven A, Fry, Terry J, Orentas, Rimas, Sabatino, Marianna, Shah, Nirali N, Steinberg, Seth M, Stroncek, Dave, Tschernia, Nick, Yuan, Constance, Zhang, Hua, Zhang, Ling, Rosenberg, Steven A, Wayne, Alan S, Mackall, Crystal L·2015·The Lancet

DOI 10.1016/s0140-6736(14)61403-3PMC PMC7065359

Open this paper in CoChat — free account

Abstract

Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)61403-3

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citation
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citation
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063

Show all 37 references

Sorted by citations

Items 801–900 of 1,006

Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 62
In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes
Naghizadeh, A., Tsao, W.-C., Cho, J. H., Xu, H., Mohamed, M., Li, D., Xiong, W., Metaxas, D., Ramos, C. A., & Liu, D. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009883 · Cited by 60
Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages
Wilson, T. L., Kim, H., Chou, C., Langfitt, D. M., Mettelman, R. C., Minervina, A. A., Allen, E. K., Métais, J., Pogorelyy, M. V., Riberdy, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1508 · Cited by 58
Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium
Medvec, A. R., Ecker, C., Kong, H., Winters, E. A., Glover, J. A., Varela‐Rohena, A., & Riley, J. L. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.001 · Cited by 64
Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system
Zhang, W., Jordan, K. R., Schulte, B., & Purev, E. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s175113 · Cited by 60
Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M.-A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.10.017 · Cited by 59
CAR T‐cell immunotherapy: The path from the by‐road to the freeway?
Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 61
Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
Tasian, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718774268 · Cited by 60
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, T., & Litzow, M. R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020198 · Cited by 58
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
Holland, E. M., Molina, J. C., DéDé, K., Moyer, D., Zhou, T., Yuan, C. M., Wang, H., Stetler‐Stevenson, M., Mackall, C. L., Fry, T. J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004483 · Cited by 59
Self-citation
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
Fusaroli, M., Isgrò, V., Cutroneo, P. M., Ferrajolo, C., Cirillo, V., Bufalo, F. D., Raschi, E., Poluzzi, E., & Trifirò, G. (2022) · Drug Safety · doi:10.1007/s40264-022-01194-z · Cited by 59
CAR-T cell-derived exosomes: a new perspective for cancer therapy
Sani, F., Shojaei, S., Tabatabaei, S. A., Khorraminejad‐Shirazi, M., Latifi, M., Sani, M., & Azarpira, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03783-4 · Cited by 66
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
Pinto, N. R., Albert, C. M., Taylor, M. R., Ullom, H. B., Wilson, A. L., Huang, W., Wendler, J., Pattabhi, S., Seidel, K. D., Brown, C., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02229 · Cited by 59
Self-citation
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Mardiros, A., Forman, S. J., & Budde, L. E. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000190 · Cited by 61
Driving better and safer HER2-specific CARs for cancer therapy
Liu, X., Zhang, N., & Shi, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17528 · Cited by 61
T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations
Ghosh, S., Carmo, M., Calero-Garcia, M., Ricciardelli, I., Bustamante‐Ogando, J. C., Blundell, M. P., Schambach, A., Ashton‐Rickardt, P. G., Booth, C., Ehl, S. R., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.050 · Cited by 59
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group
McNeer, J. L., Devidas, M., Dai, Y. E., Carroll, A. J., Heerema, N. A., Gastier, J. M., Kahwash, S. B., Borowitz, M. J., Wood, B. L., Larsen, E. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00884 · Cited by 60
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
Song, M.-K., Park, B.-B., & Uhm, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205010 · Cited by 62
Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
Magnani, C. F., Tettamanti, S., Alberti, G., Pisani, I., Biondi, A., Serafini, M., & Gaipa, G. (2020) · Cells · doi:10.3390/cells9061337 · Cited by 64
TCR β chain–directed bispecific antibodies for the treatment of T cell cancers
Paul, S., Pearlman, A. H., Douglass, J., Mog, B. J., Hsiue, E. H.-C., Hwang, M. S., DiNapoli, S. R., Konig, M. F., Brown, P. A., Wright, K. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3595 · Cited by 60
Chimeric antigen receptor T‐cell therapies: Optimising the dose
Dasyam, N., George, P., & Weinkove, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14281 · Cited by 58
Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
Xu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569117 · Cited by 62
Emerging CAR T Cell Strategies for the Treatment of AML
Vishwasrao, P., Li, G., Boucher, J. C., Smith, D. L., & Hui, S. K. (2022) · Cancers · doi:10.3390/cancers14051241 · Cited by 61
Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism
Huang, Y., Shao, M., Teng, X., Si, X., Wu, L., Jiang, P., Liu, L., Cai, B., Wang, X., Han, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101400 · Cited by 63
CAR-T cell expansion platforms yield distinct T cell differentiation states
Song, H. W., Procházková, M., Shao, L., Traynor, R., Underwood, S., Black, M. A., Fellowes, V. S., Shi, R., Pouzolles, M., Chou, H.-C., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.03.003 · Cited by 59
Self-citation
T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies
Velasquez, M. P., Torres, D., Iwahori, K., Kakarla, S., Arber, C., Rodríguez-Cruz, T., Szöőr, Á., Bonifant, C. L., Gerken, C. P., Cooper, L. J. N., et al. (2016) · Scientific Reports · doi:10.1038/srep27130 · Cited by 59
Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells
Klampatsa, A., Achkova, D., Davies, D. M., Parente‐Pereira, A. C., Woodman, N. L., Rosekilly, J., Osborne, G., Thayaparan, T., Billè, A., Sheaff, M., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.015 · Cited by 58
The why, what, and how of the new FACT standards for immune effector cells
Maus, M. V., & Nikiforow, S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0239-0 · Cited by 59
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
Mitwasi, N., Feldmann, A., Bergmann, R., Berndt, N., Arndt, C., Koristka, S., Kegler, A., Jureczek, J., Hoffmann, A., Ehninger, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21017 · Cited by 58
The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review
Jin, Z., Xiang, R., Qing, K., Li, X., Zhang, Y., Wang, L., Zhu, H., Mao, Y., Xu, Z., & Li, J. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3368-8 · Cited by 59
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
Trüb, M., Uhlenbrock, F., Claus, C., Herzig, P., Thelen, M., Karanikas, V., Bacac, M., Amann, M., Albrecht, R., Ferrara, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000238 · Cited by 58
Advanced diagnostic aids for oral cancer
Madhura, M. G., Rao, R. S., Patil, S., Fageeh, H. N., Alhazmi, A. S., & Awan, K. H. (2020) · Disease-a-Month · doi:10.1016/j.disamonth.2020.101034 · Cited by 60
Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors
Fu, R., Li, H., Li, R., McGrath, K. V., Dotti, G., & Gu, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009489 · Cited by 58
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia
Zhang, X., Yang, J., Li, J., Li, W., Song, D., Lu, X., Wu, F., Li, J., Chen, D., Li, X., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03009-z · Cited by 58
Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity
Zhao, H., Liu, Y., Wang, L., Jin, G., Zhao, X., Xu, J., Zhang, G., Ma, Y., Yin, N., & Peng, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110083 · Cited by 57
Strategic advances in liposomes technology: translational paradigm in transdermal delivery for skin dermatosis
Choudhury, A., Kirti, A., Lenka, S. S., Naser, S. S., Sinha, A., Kumari, S., Kaushik, N. K., Ghosh, A., & Verma, S. K. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03660-z · Cited by 60
Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells
Siegler, E. L., Li, S., Kim, K. G., & Wang, P. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.021 · Cited by 58
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia
Magnani, C. F., Mezzanotte, C., Cappuzzello, C., Bardini, M., Tettamanti, S., Fazio, G., Cooper, L. J. N., Dastoli, G., Cazzaniga, G., Biondi, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.207 · Cited by 59
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
Pennell, C. A., Barnum, J. L., McDonald-Hyman, C. S., Panoskaltsis‐Mortari, A., Riddle, M. J., Xiong, Z., Loschi, M. L., Thangavelu, G., Campbell, H. M., Storlie, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.006 · Cited by 59
TriKEs and BiKEs join CARs on the cancer immunotherapy highway
Tay, S. S., Carol, H., & Biro, M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1198455 · Cited by 57
Development of adaptive immune effector therapies in solid tumors
Comoli, P., Chabannon, C., Koehl, U., Lanza, F., Urbano-Ispizúa, Á., Hudecek, M., Ruggeri, A., Secondino, S., Bonini, C., & Pedrazzoli, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz285 · Cited by 57
Adoptive T-cell therapy for HBV-associated HCC and HBV infection
Tan, A. T., & Schreiber, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104748 · Cited by 58
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities
Gutiérrez, C., Brown, A. R., Herr, M. M., Kadri, S. S., Hill, B. T., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K. B., Lin, Y., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.008 · Cited by 55
Self-citation
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
Liu, P., Liu, M., Lyu, C., Lu, W., Cui, R., Wang, J., Li, Q., Mou, N., Deng, Q., & Yang, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573822 · Cited by 54
Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma
Kennedy, V. E., Wong, C., Huang, C., Kambhampati, S., Wolf, J. L., Martin, T. G., Shah, N. D., & Wong, S. W. K. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005020 · Cited by 57
Self-citation
iNKT: A new avenue for CAR-based cancer immunotherapy
Liu, Y., Wang, G., Chai, D., Dang, Y., Zheng, J., & Li, H. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101342 · Cited by 63
SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
Bidgood, G. M., Keating, N., Doggett, K., & Nicholson, S. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419951 · Cited by 61
Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations
Deniger, D. C., Yu, J., Huls, M. H., Figliola, M. J., Mi, T., Maiti, S. N., Widhopf, G. F., Hurton, L. V., Thokala, R., Singh, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128151 · Cited by 56
Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment
Arai, Y., Choi, U., Corsino, C. I., Koontz, S. M., Tajima, M., Sweeney, C. L., Black, M. A., Feldman, S. A., Dinauer, M. C., & Malech, H. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.003 · Cited by 56
Self-citation
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
Parker, C. A., Krishnan, S., Hamadeh, L., Irving, J. A. E., Kuiper, R. P., Révész, T., Hoogerbrugge, P. M., Hancock, J. P., Sutton, R., Moorman, A. V., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30003-1 · Cited by 56
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
Li, S., Xue, L., Wang, M., Qiang, P., Xu, H., Zhang, X., Kang, W., You, F., Xu, H., Wang, Y., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198567 · Cited by 58
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56
Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada
Furzer, J., Gupta, S., Nathan, P. C., Schechter, T., Pole, J. D., Krueger, J., & Pechlivanoglou, P. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5909 · Cited by 55
A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology
Lee, S. M., Kang, C. H., Choi, S. U., Kim, Y., Hwang, J. Y., Jeong, H. G., & Park, C. H. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00476 · Cited by 56
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Dunn, G. P., Cloughesy, T. F., Maus, M. V., Prins, R. M., Reardon, D. A., & Sonabend, A. M. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa154 · Cited by 56
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis
Luo, W., Li, C., Zhang, Y., Du, M., Kou, H., Lu, C., Mei, H., & Hu, Y. (2022) · BMC Cancer · doi:10.1186/s12885-021-09102-x · Cited by 57
Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products
Shao, L., Shi, R., Zhao, Y., Liu, H., Lu, A., Ma, J., Cai, Y., Fuksenko, T., Pelayo, A., Shah, N. N., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03729-5 · Cited by 56
Self-citation
Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
Nakazawa, Y., Matsuda, K., Kurata, T., Sueki, A., Tanaka, M., Sakashita, K., Imai, C., Wilson, M. H., & Koike, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0256-3 · Cited by 55
Strategies to genetically engineer T cells for cancer immunotherapy
Spear, T. T., Nagato, K., & Nishimura, M. I. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1842-5 · Cited by 54
Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy
Wang, J., Hu, Y., & Huang, H. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ru0817-315r · Cited by 57
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh, A., Mailankody, S., Giralt, S., Landgren, O., Smith, E. L., & Brentjens, R. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1393668 · Cited by 56
Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
Li, N., Liu, S., Sun, M., Chen, W., Xu, X., Zeng, Z., Tang, Y., Dong, Y., Chang, A. H., & Zhao, Q. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.10.009 · Cited by 55
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
Jain, T., & Litzow, M. R. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620719899897 · Cited by 55
Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
Wang, J., Mou, N., Yang, Z., Li, Q., Jiang, Y., Meng, J., Liu, X., & Deng, Q. (2020) · British Journal of Haematology · doi:10.1111/bjh.16623 · Cited by 57
Therapeutic Strategies for Targeting IL-1 in Cancer
Gottschlich, A., Endres, S., & Kobold, S. (2021) · Cancers · doi:10.3390/cancers13030477 · Cited by 58
Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer
Zhao, X., Cai, L., Hu, Y., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584099 · Cited by 62
Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T
Singh, A. P., Chen, W., Zheng, X., Mody, H. R., Carpenter, T. J., Zong, A., & Heald, D. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12598 · Cited by 57
Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines
Leo, I. R., Aswad, L., Stahl, M. M. S., Kunold, E., Post, F., Erkers, T., Struyf, N., Mermelekas, G., Joshi, R. N., Villacampa, E. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29224-5 · Cited by 57
CAR-T cell therapy for hematological malignancies: History, status and promise
Wang, C., Wang, J., Che, S., & Hai, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21776 · Cited by 64
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 58
Active Immunotherapy of Cancer
Chodon, T., Koya, R. C., & Odunsi, K. O. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1096684 · Cited by 54
Improving the safety of T-Cell therapies using an inducible caspase-9 gene
Zhou, X., & Brenner, M. K. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.07.011 · Cited by 57
Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy
Murad, J., Baumeister, S. H. C., Werner, L. L., Daley, H., Trebeden‐Negre, H., Reder, J., Sentman, C. L., Gilham, D. E., Lehmann, F. F., Snykers, S., et al. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.05.001 · Cited by 53
Retracted: Applications and advances of CRISPR-Cas9 in cancer immunotherapy
Xia, A., He, Q., Wang, J., Zhu, J., Sha, Y., Sun, B., & Lu, X. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105422 · Cited by 57
Retracted
Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Xiao, X., He, X., Li, Q., Zhang, H., Meng, J., Jiang, Y., Deng, Q., & Zhao, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1379 · Cited by 55
Self-citation
Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
Greenbaum, U., Mahadeo, K. M., Kebriaei, P., Shpall, E. J., & Saini, N. Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01594 · Cited by 56
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
Duault, C., Kumar, A., Khani, A. T., Lee, S. J., Yang, L., Huang, M., Hurtz, C., Manning, B. S., Ghoda, L. Y., McDonald, T., et al. (2021) · Blood · doi:10.1182/blood.2020009871 · Cited by 53
Medical management of side effects related to CAR T cell therapy in hematologic malignancies
Namuduri, M., & Brentjens, R. J. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1183479 · Cited by 53
Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
Ronson, A., Tvito, A., & Rowe, J. M. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0519-8 · Cited by 54
A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies
Lu, T., Pugach, O., Somerville, R. P. T., Rosenberg, S. A., Kochenderfer, J. N., Better, M., & Feldman, S. A. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.120 · Cited by 53
Self-citation
New Agents, Emerging Late Effects, and the Development of Precision Survivorship
Chow, E. J., Antal, Z., Constine, L. S., Gardner, R. A., Wallace, W. H., Weil, B. R., Yeh, J. M., & Fox, E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4647 · Cited by 53
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management
Beltrán, B., Castro, D., Paredes, S. R., Miranda, R. N., & Castillo, J. J. (2020) · American Journal of Hematology · doi:10.1002/ajh.25760 · Cited by 53
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells
Bai, Z., Lundh, S. M., Kim, D., Woodhouse, S., Barrett, D. M., Myers, R. M., Grupp, S. A., Maus, M. V., June, C. H., Cámara, P. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002328 · Cited by 57
Toxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 55
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
Ascierto, P. A., Atkins, M. B., Bifulco, C. B., Botti, G., Cochran, A. J., Davies, M. A., Demaria, S., Dummer, R., Ferrone, S., Formenti, S. C., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0736-1 · Cited by 53
Self-citation
Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome
Wang, L., Ma, N., Okamoto, S., Amaishi, Y., Sato, E., Seo, N., Mineno, J., Takesako, K., Kato, T., & Shiku, H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1211218 · Cited by 51
Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma
Salem, D., Marić, I., Yuan, C. M., Liewehr, D. J., Venzon, D. J., Kochenderfer, J. N., & Stetler‐Stevenson, M. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.015 · Cited by 52
Self-citation
Treatment of metastatic non‑small cell lung cancer with NY‑ESO‑1 specific TCR engineered‑T cells in a phase I clinical trial: A case report
Xia, Y., Tian, X., Wang, J., Qiao, D., Liu, X., Liang, X., Liang, W., Ban, D., Chu, J., Yu, J., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9534 · Cited by 53
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.
Neal, L. R., Bailey, S. R., Wyatt, M. M., Bowers, J. S., Majchrzak, K., Nelson, M. H., Haupt, C., Paulos, C. M., & Varela, J. C. (2017) · PubMed · Cited by 52
Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy
Innamarato, P., Kodumudi, K. N., Asby, S. C., Schachner, B. I., Hall, M. S., Mackay, A., Wiener, D. A., Beatty, M. S., Nagle, L., Creelan, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.025 · Cited by 50
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Hefazi, M., & Litzow, M. R. (2018) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s170351 · Cited by 53
CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models
León‐Triana, O., Sabir, S., Calvo, G. F., Belmonte-Beitia, J., Chulián, S., Martínez-Rubio, Á., Rosa, M., Pérez‐Martínez, A., Ramírez, M. R., & Pérez‐García, V. M. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105570 · Cited by 51
Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions
Sudarsanam, H., Buhmann, R., & Henschler, R. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.886637 · Cited by 54
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors
Hong, Y., Walling, B. L., Kim, H.-R., Serratelli, W. S., Lozada, J. R., Sailer, C. J., Amitrano, A. M., Lim, K., Mongre, R. K., Kim, K., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01498-x · Cited by 50
Immunotherapy for lung cancer: advances and prospects.
Li, Y., Wang, L., & Zhang, Y. (2016) · PubMed Central · Cited by 51
Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo
Xu, X., Song, D.-G., Poussin, M., Ye, Q., Sharma, P., Rodríguez-García, A., Tang, Y., & Powell, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10510 · Cited by 51
Antibody-Based Cancer Therapy
Hendriks, D., Choi, G., de Bruyn, M., Wiersma, V. R., & Bremer, E. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2016.10.002 · Cited by 56
Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
Ma, F., Ho, J., Du, H., Fan, X., Wu, X., Wang, Q., Wang, L., Liu, Y., Ba, M., Wang, Y., et al. (2019) · Hematological Oncology · doi:10.1002/hon.2672 · Cited by 52

Authors: Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
Affiliations: National Institutes of Health (US)
National Cancer Institute (US)
University of Nevada, Reno (US)
University of Southern California (US)
Corresponding author: Mackall, Crystal L
ORCID: Lee, Daniel W
Kochenderfer, James N
Cui, Yongzhi K
Delbrook, Cindy
Feldman, Steven A
Fry, Terry J
Orentas, Rimas
Shah, Nirali N
Steinberg, Seth M
Yuan, Constance
Zhang, Hua
Zhang, Ling
Rosenberg, Steven A
Wayne, Alan S
Mackall, Crystal L
Venue: The Lancet
Publisher: Elsevier BV
Published: 2015-02
Volume: 385
Issue: 9967
Pages: 517-528
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)61403-3
PMC: PMC7065359
OpenAlex: W2129702476
Cited by: 2,898
References: 37
Citations by year: 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
FWCI: 103.68
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: St. Baldrick's Foundation
Entertainment Industry Foundation
National Institutes of Health
National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
National Institute of Allergy and Infectious Diseases
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
MeSH terms: Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks